Catalyst Wire Dossier Catalyst Wire Dossier

RIABNI

RITUXIMAB-ARRX · Amgen, Inc
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for RIABNI, covering 2020-12-17 to 2025-06-09. Get the full timeline:

Most recent: FDA Approved: RIABNI — Supplemental Application (Amgen, Inc)

See pricing